Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$84.62NASDAQ Closing Price as of 4:00PM ET 1/27/20

Today's Change-1.53(1.78%)
Bid (Size)$84.00 (9)
Ask (Size)$84.90 (1)
Day Low / High$84.15 - 85.86
Volume1.3 M
 

View Biotechnology IndustryPeer Comparison as of 01/27/2020

 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $84.62
Change: -1.53 (1.78%)
Volume: 1.3 M
4:00PM ET 1/27/2020
 
 

Incyte Corp ( NASDAQ )

Price: $76.07
Change: -0.67 (0.87%)
Volume: 1.1 M
4:00PM ET 1/27/2020
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $117.03
Change: -2.97 (2.47%)
Volume: 884.2 K
4:00PM ET 1/27/2020
 
 

Exact Sciences Corp ( NASDAQ )

Price: $87.93
Change: -1.64 (1.83%)
Volume: 2.3 M
4:00PM ET 1/27/2020
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $110.43
Change: -3.14 (2.76%)
Volume: 1.0 M
4:00PM ET 1/27/2020
 

Read more news Recent News

Q4 Estimate for BioMarin Pharmaceuticals Reduced but 2020 Projections Increased
11:25PM ET 1/24/2020 MT Newswires

BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 86.15) Q4 quarterly and 2020 full year forecasted earnings estimates for the periods ending December...

--Analyst Actions: RBC Upgrades BioMarin Pharmaceutical to Outperform From Sector Perform, Lifts Price Target to $113 From $111
6:46AM ET 1/24/2020 MT Newswires

Price: 85.63, Change: -1.96, Percent Change: -2.24 ...

BioMarin Pharmaceuticals' 2020 Earnings Forecast Bumped Up
11:40PM ET 1/21/2020 MT Newswires

The December 31, 2020 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 87.55) has been raised. This new consensus of...

BioMarin Pharmaceuticals' 2020 Earnings Projection Lowered
11:30PM ET 1/20/2020 MT Newswires

2020`s forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 88.27) for the year ending December 31, 2020 has been...

Company Profile

Business DescriptionBioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
Address770 Lindaro Street
San Rafael, California 94901
Phone+1.415.506.6700
Number of Employees2,849
Recent SEC Filing01/16/20204
Chairman & Chief Executive OfficerJean-Jacques Bienaimé
Chief Financial Officer & Executive Vice PresidentDan Spiegelman
Chief Information OfficerEduardo E. Von Pervieux
Chief Medical Officer & Senior Vice PresidentGeoffrey M. Nichol

Company Highlights

Price Open$84.90
Previous Close$86.15
52 Week Range$62.88 - 100.13
Market Capitalization$15.2 B
Shares Outstanding179.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/20/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.17
Beta vs. S&P 500N/A
Revenue$1.5 B
Net Profit Margin-2.67%
Return on Equity-1.42%

Analyst Ratings as of 01/24/2020

Buy
19
Overweight
2
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset